Occurrence of Anterior Uveitis in Patients with Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors: Comparing the Soluble Receptor to Monoclonal Antibodies in a Large Observational Cohort

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2020 Apr 28

PMID 32336278

Citations 4

Authors

Gisele Khoury

Jacques Morel

Bernard Combe

Cedric Lukas

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to compare in real life the occurrence of anterior uveitis in patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA), treated with the soluble-receptor etanercept (ETA) or monoclonal antibodies (mAbs).

Methods: This was an observational, retrolective study. Patients with SpA who were prescribed anti-TNF agents between 2000 and 2014 were included. The risk of uveitis was interpreted qualitatively (number of subjects with at least one uveitis) and quantitatively (number of uveitis flares for each individual). Models were adjusted for propensity score of receiving preferentially mAbs or ETA.

Results: Four hundred twenty-nine patients were included (302 with SpA and 127 with PsA); 203 received a mAb and 226 ETA as a first TNF-α inhibitor. Probability of uveitis occurring during the first year of treatment was lower with ETA than with mAbs but not significantly (odds ratio 0.94 [95% confidence interval 0.35; 2.54], p = 0.90, on qualitative analysis and relative risk 0.62 [0.26; 1.46], p = 0.27, on quantitative analysis) after adjustment for the propensity score. The over-time risk of uveitis was numerically higher with ETA than with mAbs, but the differences were not statistically significant.

Conclusion: In this observational study, the risk of uveitis in patients with SpA does not appear to be greater with ETA than with mAb treatment. The occurrence of uveitis in patients receiving an anti-TNF-α agent seems linked more to the history of uveitis than the prescribed molecule.

Citing Articles

Higher frequency but similar recurrence rate of uveitis episodes in axial spondylarthritis compared to psoriatic arthritis. A multicentre retrospective study.

Kougkas N, Magiouf K, Gialouri C, Evangelatos G, Pappa M, Dimouli A Rheumatol Int. 2023; 43(11):2081-2088.

PMID: 37610650 PMC: 10495278. DOI: 10.1007/s00296-023-05424-0.

Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study.

Ahn S, Kim M, Kim Y, Lee Y, Kim Y J Clin Med. 2022; 11(3).

PMID: 35160082 PMC: 8836742. DOI: 10.3390/jcm11030631.

Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review.

Joltikov K, Lobo-Chan A Front Med (Lausanne). 2021; 8:695904.

PMID: 34568364 PMC: 8461013. DOI: 10.3389/fmed.2021.695904.

New pharmacotherapy options for noninfectious posterior uveitis.

Pleyer U, Neri P, Deuter C Int Ophthalmol. 2021; 41(6):2265-2281.

PMID: 33634341 PMC: 8172489. DOI: 10.1007/s10792-021-01763-8.

References

Savion S, Oddo S, Grover S, Caspi R . Uveitogenic T lymphocytes in the rat: pathogenicity vs. lymphokine production, adhesion molecules and surface antigen expression. J Neuroimmunol. 1994; 55(1):35-44. DOI: 10.1016/0165-5728(94)90144-9. View

Yazgan S, Celik U, Isik M, Karahan Yesil N, Baki A, Sahin H . Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2016; 37(1):139-145. DOI: 10.1007/s10792-016-0239-y. View

Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L . Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003; 48(6):1667-75. DOI: 10.1002/art.11017. View

Miserocchi E, Modorati G, Mosconi P, Colucci A, Bandello F . Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm. 2010; 18(4):297-304. DOI: 10.3109/09273941003637510. View

Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B . Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2009; 69(1):226-9. DOI: 10.1136/ard.2008.103192. View

Williamson E, Morley R, Lucas A, Carpenter J . Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res. 2011; 21(3):273-93. DOI: 10.1177/0962280210394483. View

Rosenbaum J . Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015; 34(6):999-1002. DOI: 10.1007/s10067-015-2960-8. View

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233. View

Braun J, Baraliakos X, Listing J, Sieper J . Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52(8):2447-51. DOI: 10.1002/art.21197. View

10.

Rudwaleit M, Rosenbaum J, Landewe R, Marzo-Ortega H, Sieper J, van der Heijde D . Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2016; 68(6):838-44. PMC: 5089650. DOI: 10.1002/acr.22848. View

11.

Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S . Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2008; 68(5):696-701. PMC: 2663712. DOI: 10.1136/ard.2008.092585. View

12.

van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76(6):978-991. DOI: 10.1136/annrheumdis-2016-210770. View

13.

Taylor W, Robinson P . Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis. Curr Rheumatol Rep. 2013; 15(4):317. DOI: 10.1007/s11926-013-0317-3. View

14.

Wendling D, Joshi A, Reilly P, Jalundhwala Y, Mittal M, Bao Y . Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014; 30(12):2515-21. DOI: 10.1185/03007995.2014.969368. View

15.

Schiffman R, Jacobsen G, Whitcup S . Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001; 119(6):841-9. DOI: 10.1001/archopht.119.6.841. View

16.

Hoeksema L, Los L . Vision-Related Quality of Life in Patients with Inactive HLA-B27-Associated-Spectrum Anterior Uveitis. PLoS One. 2016; 11(1):e0146956. PMC: 4725670. DOI: 10.1371/journal.pone.0146956. View

17.

Lie E, Lindstrom U, Zverkova-Sandstrom T, Olsen I, Forsblad-dElia H, Askling J . Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017; 76(9):1515-1521. DOI: 10.1136/annrheumdis-2016-210931. View

18.

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W . Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359(9313):1187-93. DOI: 10.1016/s0140-6736(02)08215-6. View

19.

Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M . Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2004; 44(3):342-8. DOI: 10.1093/rheumatology/keh475. View

20.

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View